Scinai Immunotherapeutics Ltd. (SCNI) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Scinai Immunotherapeutics Ltd. (SCNI) trades at a price-to-earnings ratio of 0.1x, with a stock price of $0.89 and trailing twelve-month earnings per share of $2.90.
The current P/E is 77% below its 5-year average of 0.6x. Over the past five years, SCNI's P/E has ranged from a low of 0.0x to a high of 1.9x, placing the current valuation at the 67th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, SCNI trades at a 99% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, SCNI trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SCNI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Vaccines and Infectious Disease peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
SCNIScinai Immunotherapeutics Ltd. | $3B | 0.1Lowest | -Best | +136% |
NVAXNovavax, Inc. | $2B | 3.9 | -Best | +310%Best |
CVACCureVac N.V. | $1B | 6.5 | -Best | +161% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $2.28 | $1.20 | 1.9x | +200% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $2.78 | $26461.60 | 0.0x | -100% |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $287.00 | $134920.00 | 0.0x | -100% |
Average P/E for displayed period: 0.6x
See SCNI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SCNI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SCNI vs AGIO
See how SCNI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SCNI stock overvalued or undervalued?
SCNI trades at 0.1x P/E, below its 5-year average of 0.6x. At the 67th percentile of historical range, the stock is priced at a discount to its own history.
How does SCNI's valuation compare to peers?
Scinai Immunotherapeutics Ltd. P/E of 0.1x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is SCNI's PEG ratio?
SCNI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2025.